HCW Biologics Inc. - 8-K Filing
HCW Biologics Inc. filed an 8-K on June 26, 2026, announcing a 1-for-6 reverse stock split effective June 30, 2026, to comply with Nasdaq's minimum bid price requirement and avoid delisting as per the May 29, 2026 decision letter from the Nasdaq Hearings Panel. The company had 9,581,079 shares outstanding pre-split and will have approximately 1,596,849 post-split after rounding fractional shares to whole shares. (Items: 3.03 Material Modification to Rights of Security Holders, 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $HCWB